Physician profile
Brian Lee
NPI 1285192765
$2,078.79
in general payments reported to CMS, 2019-2025
13 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.83 · 2023: $15.07 · 2024: $159 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $453.19 | 2025 | Rezdiffra |
| Abbvie INC. | $279.62 | 2025 | |
| Gilead Sciences, INC. | $250.01 | 2025 | Livdelzi, Epclusa |
| Ardelyx, INC. | $232.73 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $194.60 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $144.82 | 2025 | Bylvay, Iqirvo |
| Novo Nordisk INC | $124.61 | 2025 | |
| Erbe USA INC | $86.19 | 2025 | Vio3apc3 |
| Mirum Pharmaceuticals, INC. | $47.40 | 2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $41.91 | 2025 | Entyvio, Gattex |
| Mallinckrodt Hospital Products INC. | $18.46 | 2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $15.78 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.07 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.